Advertisement

Topics

FDA Grants Orphan Drug Designation to TG Therapeutics’ Umbralisib for the Treatment of Marginal Zone Lymphoma

09:13 EDT 16 Apr 2019 | Speciality Pharma Journal

NEW YORK, April 15, 2019 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to its phosphoinositide-3-kinase (PI3K) delta inhibitor, umbralisib (TGR-1202), for the treatment of patients with all three types of marginal zone lymphoma (MZL): nodal, extranodal, and splenic MZL. Umbralisib monotherapy is being …

Original Article: FDA Grants Orphan Drug Designation to TG Therapeutics’ Umbralisib for the Treatment of Marginal Zone Lymphoma

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Orphan Drug Designation to TG Therapeutics’ Umbralisib for the Treatment of Marginal Zone Lymphoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...